Table 2.
Daily rate differences in SARS-CoV-2 outcomes between unvaccinated and fully vaccinated‡ individuals by age group, by month and total study period
| Total study period (Jan 3*–April 10, 2021†) |
Monthly analysis |
||||
|---|---|---|---|---|---|
| Jan 3–31, 2021 | Feb 1–28, 2021 | March 1–31, 2021 | April 1–10, 2021† | ||
| SARS-CoV-2 infections | |||||
| Age 16–24 years | 91·9 (33·2–135·8) | 137·2 (95·2–145·4) | 114·6 (89·2–134·4) | 38·8 (18·4–88·8) | 8·5 (8·3–11·5) |
| Age 25–34 years | 83·1 (39·2–107·5) | 99·1 (73·2–108·6) | 106·4 (80·6–118·1) | 53·2 (22·3–89·6) | 16·6 (11·0–19·0) |
| Age 35–44 years | 79·3 (37·6–96·8) | 88·4 (71·5–97·7) | 91·7 (77·0–107·7) | 48·3 (31·0–87·6) | 12·6 (7·3–17·4) |
| Age 45–54 years | 83·8 (40·2–100·6) | 91·4 (71·5–104·8) | 99·6 (81·9–108·1) | 54·3 (30·7–88·6) | 13·5 (9·4–17·8) |
| Age 55–64 years | 73·7 (34·5–95·2) | 92·6 (71·2–107·7) | 87·9 (70·2–101·7) | 50·4 (23·1–77·9) | 10·3 (5·6–15·5) |
| Age 65–74 years | 51·7 (28·4–77·1) | 76·0 (59·8–88·8) | 64·3 (49·5–79·1) | 32·7 (19·7–47·2) | 12·3 (10·5–20·8) |
| Age 75–84 years | 73·8 (48·2–93·9) | 75·9 (68·1–93·2) | 90·9 (63·5–99·6) | 67·3 (38·7–82·3) | 25·4 (14·7–36·0) |
| Age ≥85 years | 88·8 (61·3–125·8) | 116·3 (91·5–156·5) | 83·6 (65·4–144·7) | 80·1 (46·6–102·5) | 18·4 (17·7–34·5) |
| Age ≥16 years | 80·0 (37·2–110·1) | 105·6 (79·4–112·1) | 103·6 (78·8–118·8) | 47·1 (24·9–86·2) | 13·2 (10·5–16·1) |
| COVID-19-related hospitalisations | |||||
| Age 16–24 years | 1·0 (0·7–1·3) | 0·8 (0·7–1·0) | 1·2 (1·0–1·6) | 1·2 (0·7–1·7) | 0·4 (0·0–0·9) |
| Age 25–34 years | 2·1 (1·5–3·0) | 1·8 (1·4–2·1) | 3·0 (2·1–3·8) | 2·4 (1·7–3·5) | 1·0 (0·5–1·5) |
| Age 35–44 years | 2·5 (1·5–4·0) | 2·2 (1·9–2·9) | 3·6 (2·5–4·8) | 3·6 (1·2–4·8) | 0·7 (0·0–1·3) |
| Age 45–54 years | 4·7 (3·1–7·1) | 3·6 (3·1–4·6) | 6·7 (5·7–7·6) | 6·0 (3·8–9·0) | 1·2 (1·2–2·4) |
| Age 55–64 years | 7·4 (5·2–10·6) | 7·3 (6·3–8·7) | 10·7 (8·8–12·1) | 7·2 (4·1–10·5) | 0·8 (0·0–1·6) |
| Age 65–74 years | 11·8 (6·8–15·4) | 13·3 (10·2–15·3) | 13·9 (9·9–17·2) | 8·3 (5·1–13·3) | 4·1 (2·1–4·2) |
| Age 75–84 years | 29·6 (21·4–37·6) | 28·7 (23·7–32·8) | 33·3 (27·7–42·9) | 32·7 (20·4–38·9) | 15·5 (14·1–21·8) |
| Age ≥85 years | 49·3 (29·6–69·3) | 56·6 (44·7–70·8) | 51·8 (40·0–71·4) | 46·2 (28·8–72·6) | 0·0 (0·0–0·0) |
| Age ≥16 years | 3·5 (2·7–4·7) | 3·2 (2·5–3·8) | 4·6 (3·4–5·5) | 3·9 (2·9–5·6) | 1·3 (1·2–1·7) |
| Severe or critical COVID-19-related hospitalisations | |||||
| Age 16–24 years | 0·1 (0·0–0·3) | 0·1 (0·0–0·1) | 0·2 (0·1–0·4) | 0·0 (0·0–0·4) | 0·0 (0·0–0·0) |
| Age 25–34 years | 0·4 (0·1–0·9) | 0·3 (0·2–0·4) | 0·7 (0·6–1·2) | 0·6 (0·0–1·2) | 0·0 (0·0–0·0) |
| Age 35–44 years | 0·9 (0·6–1·9) | 0·8 (0·6–1·2) | 1·5 (0·9–2·2) | 1·2 (0·6–2·6) | 0·0 (0·0–0·0) |
| Age 45–54 years | 3·1 (1·9–4·7) | 2·3 (1·9–3·0) | 4·2 (3·5–5·0) | 3·8 (1·8–5·7) | 0·6 (0·0–1·2) |
| Age 55–64 years | 4·7 (3·1–7·6) | 4·4 (3·3–5·9) | 7·4 (6·0–8·8) | 4·1 (2·9–7·8) | 0·0 (0·0–0·0) |
| Age 65–74 years | 8·5 (4·4–11·3) | 9·0 (7·6–11·1) | 10·8 (6·6–13·7) | 6·9 (2·0–11·2) | 1·1 (0·0–2·2) |
| Age 75–84 years | 24·2 (15·3–30·0) | 21·7 (18·0–27·0) | 28·5 (21·2–31·4) | 26·5 (13·9–34·1) | 7·7 (0·0–14·6) |
| Age ≥85 years | 39·0 (23·2–56·7) | 43·3 (32·5–61·4) | 44·5 (30·1–55·4) | 31·5 (22·9–62·1) | 0·0 (0·0–0·0) |
| Age ≥16 years | 2·0 (1·4–2·8) | 1·7 (1·4–2·1) | 2·6 (2·0–3·3) | 2·6 (1·5–3·4) | 0·4 (0·2–0·6) |
| COVID-19-related deaths | |||||
| Age 16–24 years | 0·0 (0·0–0·0) | 0·0 (0·0–0·0) | 0·0 (0·0–0·0) | 0·0 (0·0–0·0) | 0·0 (0·0–0·0) |
| Age 25–34 years | 0·0 (0·0–0·0) | 0·0 (0·0–0·0) | 0·0 (0·0–0·1) | 0·0 (0·0–0·0) | 0·0 (0·0–0·0) |
| Age 35–44 years | 0·0 (0·0–0·0) | 0·0 (0·0–0·1) | 0·0 (0·0–0·2) | 0·0 (0·0–0·0) | 0·0 (0·0–0·0) |
| Age 45–54 years | 0·1 (0·0–0·4) | 0·2 (0·1–0·3) | 0·2 (0·0–0·6) | 0·0 (0·0–0·8) | 0·0 (0·0–0·0) |
| Age 55–64 years | 0·6 (0·0–1·4) | 0·8 (0·5–1·4) | 0·7 (0·5–1·7) | 0·0 (0·0–1·4) | 0·0 (0·0–0·0) |
| Age 65–74 years | 2·5 (0·9–3·7) | 3·0 (2·3–4·5) | 2·7 (1·2–4·0) | 2·0 (0·0–3·6) | 0·0 (0·0–0·0) |
| Age 75–84 years | 9·1 (4·6–13·6) | 10·6 (7·4–13·6) | 10·5 (6·7–15·7) | 6·5 (0·0–13·5) | 0·0 (0·0–0·0) |
| Age ≥85 years | 20·2 (9·4–35·4) | 29·1 (20·8–37·3) | 24·1 (17·3–35·7) | 15·2 (0·0–38·9) | 0·0 (0·0–0·0) |
| Age ≥16 years | 0·5 (0·3–0·7) | 0·6 (0·4–0·7) | 0·5 (0·3–0·6) | 0·6 (0·3–0·7) | 0·0 (0·0–0·1) |
Data are median daily rate difference (IQR) per 100 000 population.
*
Jan 3, 2021, corresponds to the first day on which people could be at least partly vaccinated.
†
April 10, 2021, was the last day of the analysis period.
‡
Fully vaccinated individuals were defined as people who received two doses of BNT162b2 with at least 7 days of follow-up after the second dose.